Indivior (INDV) and Reckitt Benckiser Healthcare have agreed to accelerate the termination date of their copacker supply agreement for Suboxone and Subutex tablets on Jan. 15, 2027, Indivior said in a regulatory filing on Tuesday.
According to the statement, Indivior said it has found a new supplier.
The current supply agreement, under which Reckitt Benckiser manufactures the tablets for Indivior, was originally agreed to in 2014, the company said.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.